in this issue
Markets :: Fine Chemicals/Biotech :: Pharmaceutical ingredients
Lonza Breaks Ground on Singapore Biologics Plant
April 25, 2007 | Chemical Week Editorial Staff
Lonza and Bio*One Capital (Singapore) have broken ground on a previously announced project to build a large-scale commercial mammalian cell culture manufacturing facility in Singapore (CW, Dec. 13, 2006, p. 29). The plant is being built in the Tuas Biomedical Park, and will be Lonza’s second large-scale mammalian manufacturing plant in Singapore and its third worldwide. It will have up to four mammalian bioreactor trains, each with a flexible capacity of 1,000 liters-20,000 liters. Completion is scheduled by 2011. The investment could total $350 million...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee